欧州における分子診断市場の戦略的分析

Abstract

Molecular Diagnostics Provide Novel Information to Physicians and Patients

With growing levels of technological automation and throughput processing rates, molecular diagnostics has been recognized as one of the fastest growing markets in the European in vitro diagnostics (IVD) industry. Its ability to sensitively and distinctly detect the primary cause of diseases is unprecedented in medicine. These tests seek to supplement or replace traditional laboratory tests and established standards of care and clinical utility. However, molecular diagnostics have to undergo clinical tests and trials to demonstrate that the information provided by them improves the quality of decision-making and patient care by physicians.

This Frost & Sullivan research service provides an overview of and an outlook for the molecular diagnostics markets in Europe, detailing revenue forecasts by region and providing market share analyses. The study defines molecular diagnostics to include diagnosis of infectious diseases, cancer and pharmacogenomics. The information offered by this exhaustive study can prove valuable to both large and small participants seeking to position themselves in these highly competitive markets.

Infectious Disease Diagnostics Boost Molecular Diagnostics Revenues in Europe

In 2004, the infectious disease diagnostics segment contributed up to 80.0 per cent to the European molecular diagnostics markets, indicating high end-user acceptance of them. Cancer and pharmacogenomic diagnostics generated 10.0 per cent of revenues in 2004. "Cancer diagnostics, representing an alternative to the conventional testing methods for cancer could, based on feedback received, introduce tests that are simple, quick, easily accessible and ensure trouble-free reimbursement, " says the analyst of this research service. "On the other hand, pharmacogenomics, though still developing, holds immense potential to develop into a lucrative market as the demand for personalised medicine increases."

New Technologies in Molecular Diagnostics Can Support Point-of-Care Tests

In 2004, the total European molecular diagnostics market generated revenues of $442.0 million with a growth rate of 10.0 per cent. This is likely to increase in the coming five to six years as alternative solutions are introduced into the market. "New technologies with the potential to reduce labour costs and improve turn-around times can provide convenience and portability that support point-of-care tests, eventually contributing to an increase in market revenues," observes the analyst.

Overall, molecular diagnostics, with a clear emphasize on early disease detection, has gained from successful campaigns across Europe that encourage people to screen for diseases. Consistent screening helps in reducing negative outcomes arising due to non-diagnosis of conditions. In addition, while screening for heritable diseases is complex, predisposition testing can throw light on the hereditary risks involved, thus making screening for early detection crucial.

Table of Contents

• 1. Strategic Analysis of the European Molecular Diagnostics Markets
  • 1. Research and Methodology
    • 1. Research and Methodology
  • 2. Introduction and Segmentation
    • 1. Glossary of Scientific Abbreviations
    • 2. Molecular Diagnostics Market: Background
    • 3. Molecular Diagnostics Market: Market Segmentation
  • 3. Total Molecular Diagnostics Market
    • 1. Overview
    • 2. Market Engineering Measurements
    • 3. Market Lifecycle
    • 4. Key Market Challenges
    • 5. Revenue Analysis
    • 6. Technology Trends
    • 7. End-user Types
    • 8. Geography Trends
    • 9. Revenue Forecasts
  • 4. Infectious Disease Market
    • 1. Market Overview
    • 2. Market Engineering Measurements
    • 3. Key Market Trends
    • 4. Customer Priorities
    • 5. Revenue Forecasts
    • 6. Top Five Market Participants Companies
  • 5. Cancer Diagnostics Market
    • 1. Market Overview
    • 2. Market Engineering Measurements
    • 3. Key Market Trends
    • 4. Applications
    • 5. Revenue Forecasts
    • 6. Top Five Market Participants
  • 6. Pharmacogenomics Market
    • 1. Market Overview
    • 2. Market Engineering Measurements
    • 3. Key Market Trends
    • 4. Revenue Forecasts
    • 5. Top Five Market Participants
  • 7. Competitive Landscape
    • 1. Tiers of Competition for Molecular Diagnostic Companies
    • 2. Molecular Diagnostics Market: Top 5 Market Participants
    • 3. Company Profiles
  • 8. Strategic Analysis and Recommendations
    • 1. Strategic Analysis and Recommendations
  • 9. Frost & Sullivan Awards
    • 1. Introduction
    • 2. Competitive Strategy Leadership Award
    • 3. Product Innovation Award
  • 10. Industry Participants
    • 1. Industry Participants
  • 11. Decision Support Databases
    • 1. Decision Support Databases